Journal
TRANSLATIONAL NEUROSCIENCE IN PSYCHIATRY
Volume 1344, Issue -, Pages 1-11Publisher
BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.12725
Keywords
translational; psychiatry; biomarker; electroencephalography; glutamate; ketamine
Categories
Ask authors/readers for more resources
Neuroscience has made tremendous progress delineating the cellular and molecular processes important for understanding neuronal development and behavior, but this knowledge has been slow to translate to new treatments for psychiatric illness. To accelerate this transfer of knowledge to the human condition requires the wide-scale adoption of biomarkers that can bridge preclinical and clinical discoveries, and serve as surrogate measures of efficacy before commencing expensive phase III studies. Several biomarker methodologies, including imaging, electroencephalography (EEG), and blood transcriptomics/proteomics, are now showing promise. From an industry perspective, we highlight the utility of quantitative EEG as one example of a translatable biomarker applicable to psychiatric drug development and discuss recent insights into glutamate system dysfunction in schizophrenia and depression gained through translational studies of the drug ketamine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available